intracranial atherosclerotic disease
Conditions
Interventions
tirofiban group:give tirofiban
non-tirofiban group:not give tirofiban
Sponsors
The First Affiliated Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. aged 50-80 yeas, male or female; 2. mRS <= 2; 3. symptomatic intracranial atherosclerotic disease (TIA or stroke) within 90 days; 4. the lesion was certified by DSA, incluing MCA-M1,BA,the intracranial segment of ICA or VA; 5. the stenosis degree was 70%-99% determined by WASID; 6. the etiological type is large artery atherosclerotic; 7. with written consent.
Exclusion criteria
Exclusion criteria: 1. aucte ischemic stroke within 1 week; 2. perforator stroke; 3. with tandem lesions; 4. anatomic tortuosity, the stent might not be placed; 5. non-atherosclerotic stenosis: such as dissection, moyamoya, et al; 6. cardiogenic stroke; 7. with tumor, aneurysm; 8. with the history of stenting in ex- or intracranial artery; 9. with the history of intracranial hemorrhage; 10. with thrombosisi within 24 hours befor group; 11. with neurological deterioration withn 24 hours; 12. with SAH within 30 days; 13. with myocardial infarction within 30 days; 14. with operation within 30 days; 15. be allergic to the drugs or devices; 16. ejection fraction <= 40%; 17. HB <= 100g/L, PLT <= 100*10^9/L; 18. severe dysfunction of liver or kidney; 19. active peptic ulcer; 20. life expectancy < 12 months; 21. can not complete the follow-up; 22. on other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of in-stent thrombosis;periprocedural new-onset stroke events;the incidence of symptomatic intracranial hemorrhage during periporcedure; | — |
Secondary
| Measure | Time frame |
|---|---|
| the DWI abnormity of periprocedural;the incidence of in-stent restenosis at 6 months;the ischemic events within 30 days;the residual stenosis after stenting;the incidence of asymptomatic intracranial hemorrhage during periprocedure;the incidence of bleeding other than the intracranial;the reduction of platelet; | — |
Countries
China
Contacts
Public ContactJu Han
The First Affiliated Hospital of Shandong First Medical University
Outcome results
None listed